Arcus Biosciences, Inc. (RCUS) return on equity (ROE)

Return on equity · fiscal 2025
-55.9%

Arcus Biosciences, Inc. (RCUS) earned a return on equity of -55.9% in fiscal 2025 (the year ended December 31, 2025). That is 2.4 percentage points higher than the -58.4% of fiscal 2024. Figures as of 17 Nov 2026, 20:54 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-55.9%
Change on fiscal 2024
+2.4 pts
Highest on record
6.3%fiscal 2021
Lowest on record
-66.5%fiscal 2023
Fiscal years on record
82018–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Arcus Biosciences, Inc. return on equity (ROE), in more detail

Across the 8 fiscal years on record (2018–2025), the highest was 6.3% in fiscal 2021 and the lowest -66.5% in fiscal 2023. The fiscal 2025 figure is higher than in 29% of the 7 earlier fiscal years on record, whose median is -40.6%.

History · 8 fiscal years

Return on equity by fiscal year

Arcus Biosciences, Inc. return on equity (ROE), year by year

Arcus Biosciences, Inc. (RCUS) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-55.9% 2.4 pts up
2024-58.4% 8.1 pts up
2023-66.5% 25.8 pts down
2022-40.6% 46.9 pts down
20216.3% 30.8 pts up
2020-24.5% 27.2 pts up
2019-51.7% 30.5 pts down
2018-21.1%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on RCUS

Arcus Biosciences, Inc., figure by figure

Arcus Biosciences, Inc. (RCUS) overview: price, valuation and scorecard

Arcus Biosciences, Inc. return on equity (ROE): questions and answers

What is Arcus Biosciences, Inc.'s return on equity?

Arcus Biosciences, Inc. (RCUS) earned a return on equity of -55.9% in fiscal 2025 (the year ended December 31, 2025). That is 2.4 percentage points higher than the -58.4% of fiscal 2024.

Is Arcus Biosciences, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 29% of the 7 earlier fiscal years on record, whose median is -40.6%.

What are the highest and lowest return on equity figures on record for Arcus Biosciences, Inc.?

Across the 8 fiscal years on record (2018–2025), the highest was 6.3% in fiscal 2021 and the lowest -66.5% in fiscal 2023.

How is Arcus Biosciences, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Arcus Biosciences, Inc. (RCUS) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/RCUS/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.